Total Payments
$175,709
2024 Payments
$4,191
Companies
7
Transactions
97
Payment Breakdown by Category
Consulting$140,494 (80.0%)
Travel$15,277 (8.7%)
Other$12,204 (6.9%)
Research$6,390 (3.6%)
Food & Beverage$1,344 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $140,494 | 58 | 80.0% |
| Travel and Lodging | $15,277 | 9 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,205 | 7 | 6.9% |
| Unspecified | $6,390 | 9 | 3.6% |
| Food and Beverage | $1,344 | 14 | 0.8% |
Payments by Type
General
$169,319
88 transactions
Research
$6,390
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sarepta Therapeutics, Inc. | $101,032 | 22 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $48,471 | 45 | $0 (2024) |
| SANOFI US SERVICES INC. | $23,969 | 22 | $0 (2023) |
| GENZYME CORPORATION | $1,449 | 1 | $0 (2017) |
| Genentech USA, Inc. | $487.53 | 5 | $0 (2019) |
| Inspire Medical Systems, Inc. | $178.40 | 1 | $0 (2024) |
| Shire North American Group Inc | $122.83 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,191 | 4 | SANOFI-AVENTIS U.S. LLC ($4,013) |
| 2023 | $4,492 | 6 | SANOFI-AVENTIS U.S. LLC ($3,676) |
| 2022 | $6,490 | 8 | SANOFI-AVENTIS U.S. LLC ($4,855) |
| 2021 | $14,308 | 13 | SANOFI-AVENTIS U.S. LLC ($9,432) |
| 2020 | $5,706 | 4 | SANOFI-AVENTIS U.S. LLC ($3,312) |
| 2019 | $28,922 | 9 | Sarepta Therapeutics, Inc. ($22,000) |
| 2018 | $85,643 | 27 | Sarepta Therapeutics, Inc. ($70,419) |
| 2017 | $25,958 | 26 | Sarepta Therapeutics, Inc. ($8,613) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,444.00 | General |
| Category: Genetic Disease | ||||||
| 10/03/2024 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $908.00 | General |
| Category: Genetic Disease | ||||||
| 05/08/2024 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,660.60 | General |
| Category: Genetic Disease | ||||||
| 02/22/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $178.40 | General |
| Category: NEUROLOGY | ||||||
| 07/27/2023 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $880.00 | General |
| Category: Genetic Disease | ||||||
| 07/27/2023 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $440.00 | General |
| Category: Genetic Disease | ||||||
| 07/25/2023 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,021.50 | General |
| Category: Genetic Disease | ||||||
| 06/29/2023 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $454.00 | General |
| Category: Genetic Disease | ||||||
| 01/17/2023 | SANOFI US SERVICES INC. | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $816.00 | General |
| Category: Genetic Disease | ||||||
| 01/10/2023 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $880.00 | General |
| Category: Genetic Disease | ||||||
| 12/27/2022 | SANOFI-AVENTIS U.S. LLC | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| Category: Genetic Disease | ||||||
| 07/19/2022 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $880.00 | General |
| Category: Genetic Disease | ||||||
| 07/19/2022 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $794.50 | General |
| Category: Genetic Disease | ||||||
| 07/18/2022 | SANOFI US SERVICES INC. | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $615.00 | General |
| Category: Genetic Disease | ||||||
| 06/21/2022 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| Category: Genetic Disease | ||||||
| 04/21/2022 | SANOFI-AVENTIS U.S. LLC | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| Category: Genetic Disease | ||||||
| 03/02/2022 | SANOFI US SERVICES INC. | XENPOZYME (Biological) | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: Genetic Disease | ||||||
| 02/18/2022 | SANOFI-AVENTIS U.S. LLC | NEXVIAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $880.00 | General |
| Category: Genetic Disease | ||||||
| 12/22/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $724.50 | General |
| 12/10/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 09/01/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,035.00 | General |
| 06/25/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 04/05/2021 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 03/30/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $307.50 | General |
| 03/22/2021 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $1,428.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASMD Pediatric C | SANOFI US SERVICES INC. | $4,568 | 5 |
| NeoGAA LTS13769 Central Costs | SANOFI US SERVICES INC. | $1,823 | 4 |
About Dr. Thomas Kinane, MD
Dr. Thomas Kinane, MD is a Pediatrics healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861482770.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Kinane, MD has received a total of $175,709 in payments from pharmaceutical and medical device companies, with $4,191 received in 2024. These payments were reported across 97 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($140,494).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Pulmonology
- Location Boston, MA
- Active Since 10/24/2005
- Last Updated 05/15/2012
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1861482770
Products in Payments
- EXONDYS 51 (Drug) $79,032
- Exondys 51 (Drug) $22,000
- GZ402666 (Drug) $16,146
- NO PRODUCT DISCUSSED (Drug) $15,697
- NEXVIAZYME (Biological) $11,518
- GZ402665 (Drug) $6,003
- XENPOZYME (Biological) $3,476
- Xolair (Biological) $487.53
- INSPIRE (Device) $178.40
- CUVITRU (Biological) $122.83
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Boston
Dr. R Ezekowitz, Mbch Dphl, MBCH DPHL
Pediatrics — Payments: $1.2M
Pediatrics $1.2M
Stephen Pelton, Md, MD
Pediatrics — Payments: $456,322
Pediatrics $456,322
Tanya Laidlaw, M.d, M.D
Pediatrics — Payments: $307,922
Pediatrics $307,922
Dr. Harald Jueppner, Md, MD
Pediatrics — Payments: $202,618
Pediatrics $202,618
Rachael Grace, Md, MD
Pediatrics — Payments: $175,958
Pediatrics $175,958
Courtney Hanna
Pediatrics — Payments: $149,231
Pediatrics $149,231